April 10 Looms as Eli Lilly’s Next Big Test: Is the Stock a Buy Before the FDA Verdict?

Life Science

An Institution Increases Holdings in Sotera Health Against the Trend

Life Science

A Tale of Two Pharma Giants — Bet on the Future or Cash In on Dividends?

Life Science

Jamieson Wellness: Unlocking the Investment Potential Behind the Green Cap

Consumer Goods, Life Science

Hims & Hers Joins Hands with Former Rival, Hidden Concerns Loom Over the Weight Loss Drug Market Landscape

Life Science

Two Top Analysts Just Upgraded Edgewise Therapeutics. Here’s Why.

Life Science

How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era?

Life Science

Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally

Life Science

Logos Bought, Alpine Sold: Is Immunovant a Buy or a Red Flag?

Life Science

Three Berkshire-Related Stocks Worth Watching: Chevron, Domino’s Pizza, and DaVita

Consumer Goods, Life Science

Top Five Cloud Computing ETF Recommendations for 2026

Life Science

Novo Nordisk Partners with Hims & Hers: Can Turning a Foe into a Friend Reverse the Downturn?

Life Science

Why Microsoft Is a Safe Bet in the AI Era, Despite Moderate Stock Gains

Life Science, Technology

Is GeneDx, the Stock Cathie Wood Bought for 7 Straight Days, Actually Cheap?

Life Science

Seeking a Bottom in Choppy Markets? Two Long-Term Picks with “Anti-Fragile” Qualities

Life Science, Technology